T-cell Developmental Status in Patients With Malignant Hematological Tumors

Inclusion Criteria:

1. Age ≥ 18 years; both genders included; expected survival > 3 months;

2. Cohort 1: Patients with newly diagnosed or relapsed B-cell lymphoma confirmed byhistopathology, bone marrow pathology, flow cytometry, morphology, and genetictesting; Cohort 2: Patients with newly diagnosed or relapsed multiple myelomaconfirmed by the same methods; Cohort 3: Healthy volunteers;

3. Able to understand and voluntarily sign the informed consent form.

Exclusion Criteria:

1. Significant pulmonary disease: Chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1second (FEV1) <50% of predicted normal value. Note: Suspected COPD cases requireFEV1 testing; subjects with FEV1 <50% of predicted must be excluded. Moderate/severe persistent asthma within the past 2 years, or currently uncontrolledasthma of any severity. (Note: Controlled intermittent or mild persistent asthma ispermitted.)

2. Symptomatic congestive heart failure (NYHA Class II-IV), symptomatic/uncontrolledarrhythmias, congenital long QT syndrome, or corrected QT interval (QTc) >500 ms (Fridericia formula) at screening.

3. History of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-relatedpneumonitis, or severely impaired lung function.

4. HIV infection (positive HIV-1/2 antibodies) or known syphilis infection.

5. Unhealed wounds, fractures, gastroduodenal ulcers, persistent fecal occult bloodpositivity, ulcerative colitis, or other conditions at risk of gastrointestinalbleeding/perforation (as determined by the investigator).

6. Severe neurological/psychiatric disorders, immunodeficiency, hepatitis/cirrhosis, orother conditions deemed unsuitable for study participation by the investigator.